# Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Study · id `cardio:ct-nct01193101` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01193101](<https://clinicaltrials.gov/study/NCT01193101>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01193101

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 389 participants.

## Technical summary

Registry record NCT01193101. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-04 (actual). Results posted on 2015-08-19.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 389 participants (enrolled count; ClinicalTrials.gov record NCT01193101, source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01193101, source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)
- Primary completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01193101, source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01193101, source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)
- Results first posted: 2015-08-19 (ClinicalTrials.gov record NCT01193101, source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)
- Countries: China; Japan; South Korea; Taiwan; Thailand (ClinicalTrials.gov record NCT01193101, source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01193101-2016-02-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): LCZ696
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study (`cardio:pubmed-24446062`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8bf0bd237d5afdf5354b3d64f9301e724cbcd932ec969a51625cf6779fa3aaf2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
